Aviva’s Altimmune ALT Stock Holding History

Aviva’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-22,954	Closed	-$153K	–	886
2024 Q2	$153K	Hold	22,954	–	–	﹤0.01%	911
2024 Q1	$234K	Hold	22,954	–	–	﹤0.01%	938
2023 Q4	$258K	Hold	22,954	–	–	﹤0.01%	930
2023 Q3	$59.7K	Hold	22,954	–	–	﹤0.01%	960
2023 Q2	$81K	Buy	+22,954	New	+$103K	﹤0.01%	960

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Aviva's ALT Position: Q3 2024 in Review

Aviva sold out of Altimmune (ALT) in Q3 2024, closing a stake of 22,954 shares — an estimated $153K sold.

Aviva first reported a position in ALT in Q2 2023 and held it in 5 quarters. The position peaked at $258K in Q4 2023. 169 funds tracked by Wall St. Rank hold ALT as of Q3 2024.

Aviva reported no remaining Altimmune position as of Q3 2024 after selling out during the quarter.
Aviva sold 22,954 Altimmune shares in Q3 2024, an estimated $153K.
Aviva first reported a position in Altimmune in Q2 2023 and held it in 5 quarters.
Aviva's Altimmune position peaked at $258K in Q4 2023.
169 funds tracked by Wall St. Rank held Altimmune as of Q3 2024.

Based on Aviva's 13F filing for Q3 2024, filed 14 Nov 2024.